Sept 13, 2022
Mizanur Rahman, co-founder, and CTO of NemaLife, has received a prestigious entrepreneurship development award from the National Institute on Aging. The award provides $400,000 in funding to pursue an industry mentor-guided project to screen a library of compounds for sarcopenia therapeutics and provide business training to commercialize the discovered hits. We are grateful to Kelsey Moody, PhD, MBA, CEO, and Founder of Ichor Life Sciences, Inc., for mentoring Mizan and supporting us in this application.
July 12, 2022
“In vitro testing is awkward,” Dhaval Patel, Ph.D., director of research and innovation at NemaLife told BioSpace. “It doesn’t give you whole organism data. So, for example, you could be looking at a neurodegenerative disease and testing only in neurons and what you might find out later is that the drug causes hepatic toxicity. You wouldn’t know that from the in vitro screen, so many false positives could move forward.”
July 7, 2022
"When the human genome was sequenced, clinical researchers envisioned an era when our personal genomic information could be used to tailor medical treatments to fit the needs of each individual, explained Walhout. Despite the completion of the Human Genome Project in 2003, and advancements in genomics and deep sequencing technologies, personalized medicine remains more promise than reality."
June 13, 2022
AI and the cloud supercharge NemaLife’s process. Instead of manual observation, the worms can be continuously monitored via video or regular pictures throughout the experiment. And yet, the benefits of digital observation would go for naught if a human then had to manually go through and record all the worm’s behavior. NemaLife solves this by collecting the video data and processing it through artificial intelligence, cleaning it up so that it can be uploaded to a client dashboard.
June 9, 2022
A major milestone has been reached to modernize #FDA’s regulatory approach. Currently, 100 million mice are used in the US alone for testing with mixed results and leaving a large negative environmental impact due to animal husbandry operations. Alternative methods of testing including NemaLife’s invertebrate screening platform will be a frontier technology driving this modernization in Pharma, FoodTech and CPG industries.
May 4, 2022
NemaLife is excited to announce a strategic technology development partnership and investment with Motif Foodworks. This partnership will accelerate the use of NemaLife’s unique in vivo testing and protein characterization platform within the food and beverage industry. Our proprietary technology enables Motif to test its novel ingredients early on in the R&D cycle using ultra-low sample volumes. This allows Motif to de-risk product development in the search for the safest and best functional food technologies with improved taste, texture, and nutrition.
Apr 19, 2022
NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens. This partnership will enable the Olson Lab to quickly examine the vast psychoplastogen chemical space in the search for new neurotherapeutics.
Apr 19, 2022
DEA registered NemaLife Inc. to work with Schedule 1 substances
NemaLife Inc., completed its DEA schedule 1 registration. If you have scheduled compounds (schedule 1-5) to test reach out to our expert for a free consultation.
Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development
Our project combines NemaLife’s microfluidic in vivo screening platform with new AI tools to perform high-throughput behavioral screens to identify new therapeutics for cocaine addiction.
March 14, 2022
Canopy Growth Corporation's Vice President of Human & Animal Research,
Dr. Marcel Bonn-Miller is giving a talk about the long-term effects of cannabigerol (CBG) in mice and nematodes at the CannX Medical Cannabis Conference. Similar to CBD, CBG is a phytocannabinoid, with an increasing presence in the worldwide ‘cannabis’ marketplace. Despite the growing pre-clinical literature, no formal toxicity studies had been carried out using CBG
before this study, which includes data from NemaLife's in vivo toxicity platform.
Jan 18, 2022
DEA registered NemaLife Inc. to work with Schedule 2-5 substances
NemaLife Inc., completed its DEA schedule 2-5 registration. If you have scheduled compounds to test reach out to our expert for a free consultation.
July 20, 2021
Loss of muscle mass and strength in astronauts remains an issue for space exploration. C. elegans shares common traits with humans and these worms are a good, cost-effective model for studying the effects of spaceflight on muscle. A NASA-funded research team has developed a new device called the NemaFlex chip to measure muscle strength over multiple generations of worms born and raised on the International Space Station (ISS).
Nov 20, 2020
Oct 23, 2020
The NemaLife chip is a simple and low-cost means to obtain reliable lifespan and physiological data on aging animals. The NemaLife chip can be developed into a fully automated platform, that can offer progeny removal, feeding, drug delivery, and phenotypic scoring using automated pump systems and an appropriate software.
New Approaches for Incorporating Genetic Diversity into Toxicity Testing
Our study aims to combine state-of-the art advances in microfluidics, computer vision, laboratory automation and a massively curated genetically diverse nematode species to produce a new screening approach capable of testing thousands of chemicals relevant to agriculture, nutraceutical and biotech markets.
Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimer’s Disease (AD/ADRD)
Our multi-prong approach is expected to de-risk drug failure in mammalian AD models. In summary, we will use a novel NemaLife technology to identify a subset of pharmacological longevity interventions will exert neuroprotection against AD-relevant stresses.
March 26, 2020
Interview with Marton Toth
"We’ve started providing small-scale services for billion dollar companies in this space who are testing our services, The obvious primary target markets are cosmetic and pharmaceutical companies – their current models and operation offer the most seamless integration of our services. All the global pharmaceutical companies are sitting on hundreds of thousands of chemicals in their compound libraries that could be tested for their Longevity effects, but there’s no viable technology for that at the moment.”
Dec 4, 2019
Interview with Siva Vinapalli
Katherine White sits down with Siva Vanapalli, a professor of chemical engineering at Texas Tech University and also Co-founder and CEO of Nemalife, a biotech and scientific community dedicated to identifying molecules that promote healthy human life. In this podcast they discuss how the Innovation Hub at Research Park helped launch his company.